What is the preferred polymyxin for treating pneumonia caused by multidrug‑resistant Gram‑negative organisms?

Preferred Polymyxin for Multidrug-Resistant Gram-Negative Pneumonia

For pneumonia caused by multidrug-resistant Gram-negative organisms, use intravenous polymyxin (either colistin or polymyxin B) combined with adjunctive inhaled colistin, as this approach reduces mortality, treatment failure, and pathogen eradication failure compared to intravenous therapy alone. 1, 2, 3

Intravenous Polymyxin: Colistin vs Polymyxin B

Both colistin (polymyxin E) and polymyxin B are acceptable for intravenous use, with no definitive superiority of one over the other based on current evidence 1. However, there are important pharmacokinetic considerations:

• Polymyxin B may have theoretical pharmacokinetic advantages over colistin for intravenous administration, though clinical data in HAP/VAP patients remain limited 1
• Both agents demonstrate similar efficacy and nephrotoxicity profiles when used intravenously 2

Dosing Considerations

Colistin (as colistimethate sodium - CMS):

• Loading dose: 5 mg/kg IV × 1
• Maintenance: 2.5 mg × (1.5 × CrCl + 30) IV q12h 1
• Dosing conversion: 1 million IU = 80 mg CMS = 33 mg colistin base activity (CBA) 2

Polymyxin B:

• 2.5-3.0 mg/kg/day divided in 2 daily IV doses 1
• 1 mg = 10,000 units 2

Inhaled Polymyxin: Critical Addition

Adjunctive inhaled colistin is strongly recommended for carbapenem-resistant pneumonia 1, 2. The evidence supporting this approach is compelling:

• Inhaled plus IV polymyxin reduces 28-day mortality by 33-40% compared to IV alone (OR 0.67,95% CI 0.50-0.88) 3, 4
• Significantly improves microbiological eradication (OR 2.70,95% CI 1.90-3.90) 3
• Achieves substantially higher epithelial lining fluid (ELF) concentrations (median 116.72 mg/L at 2 hours post-inhalation vs. minimal penetration from IV alone) 5, 6
• Pathogen eradication rate of 72.4% when nebulized polymyxin used 7

Why Colistin for Inhalation?

Colistin is preferred over polymyxin B for nebulization 1, 2:

• Inhaled colistin has demonstrated pharmacokinetic advantages and controlled clinical trial evidence
• Inhaled polymyxin B data comes primarily from anecdotal/uncontrolled studies
• Critical safety note: Colistin for inhalation must be administered promptly after mixing with sterile water (FDA warning after fatal case with premixed formulation) 1

Nebulization Protocol

• Dose: 50-75 mg colistin twice daily via nebulizer 8, 7
• Duration: 7-15 days (median 9 days) 7
• Delivery methods: Jet nebulizer, vibrating-mesh nebulizer, or ultrasonic nebulizer for spontaneously breathing patients; ventilator-integrated for mechanically ventilated patients 2
• Bronchospasm incidence: 3.3-7.5%, manageable with inhaled corticosteroids and β2-agonists without discontinuation 8, 7

Combination Therapy Strategy

Polymyxin should NOT be used as monotherapy for serious CRGNB infections 2:

• Combination therapy reduces treatment failure by 11.9% (RR 0.82,95% CI 0.72-0.93) and pathogen eradication failure by 7.4% (RR 0.81,95% CI 0.67-0.98) 2
• Preferred combinations:
  • Polymyxin + carbapenem (meropenem): Use when meropenem MIC ≤8 mg/L for CRE or ≤32 mg/L for CRAB, with high-dose extended-infusion meropenem (3-hour infusion) 2
  • Colistin-carbapenem combinations ranked first in clinical cure (SUCRA 91.7%) for CRAB pneumonia 2

Safety Monitoring

Nephrotoxicity is the primary concern:

• Acute kidney injury incidence: 15% with combined IV+inhaled therapy 8
• Inhaled monotherapy has significantly lower nephrotoxicity than IV (p=0.025) 9, but is less effective for mortality reduction
• Early nephrotoxicity (day 3) predicts late nephrotoxicity (OR 39.43,95% CI 7.64-203.62) 10
• Monitor renal function before treatment and on days 3 and 7 2, 10
• Therapeutic drug monitoring (TDM) is encouraged where available 2
• Avoid concurrent nephrotoxic/ototoxic drugs 2

Clinical Algorithm

1. Confirm carbapenem-resistant Gram-negative pneumonia (Acinetobacter, Pseudomonas, Klebsiella)
2. Initiate IV polymyxin (colistin or polymyxin B with loading dose)
3. Add inhaled colistin within 24 hours (50-75 mg twice daily)
4. Combine with carbapenem if MIC permits (see thresholds above)
5. Monitor renal function on days 0,3, and 7
6. Continue for 7-15 days based on clinical response
7. Watch for bronchospasm (treat without discontinuing if occurs)

Predictors of Poor Outcome

Early identification of high-risk patients guides escalation:

• Procalcitonin >1.2 ng/mL 8
• CRP >45 mg/L 8
• PaO2/FiO2 <250 8
• APACHE II score elevation 10
• Polymicrobial infection 10

These patients may require more aggressive combination strategies and closer monitoring.